4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0001567619-22-021291
Chief Legal and HR Officer sold 6,000 shares at an average $22.79 ($136,725)
- Chief Legal and HR Officer acquired 5,625 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Bizily Scott · Chief Legal and HR Officer
Table I: Non-derivative
11 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-12-01 | Exercise or conversion : show line 1 in the form | +1,875 | $6.49 | $12,169 | 4,732 | D |
| 2022-12-01 | Sale : show line 2 in the form | −400 | $21.52 | $8,606 | 4,332 | D |
| 2022-12-01 | Sale : show line 3 in the form | −975 | $22.71 | $22,147 | 3,357 | D |
| 2022-12-01 | Sale : show line 4 in the form | −400 | $23.25 | $9,300 | 2,957 | D |
| 2022-12-01 | Sale : show line 5 in the form | −100 | $24.49 | $2,449 | 2,857 | D |
| 2022-12-01 | Exercise or conversion : show line 6 in the form | +3,750 | $8.04 | $30,150 | 6,607 | D |
| 2022-12-01 | Sale : show line 7 in the form | −1,000 | $21.78 | $21,775 | 5,607 | D |
| 2022-12-01 | Sale : show line 8 in the form | −2,450 | $22.93 | $56,180 | 3,157 | D |
| Open-market sales · 6,000 sh · avg $22.79 · $136,725 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-12-01 | Exercise or conversion : show line 12 in the form Stock Option (Right to Buy) | −1,875 | 22,125 | D |
| 2022-12-01 | Exercise or conversion : show line 13 in the form Stock Option (Right to Buy) | −3,750 | 56,250 | D |
Loading xslF345X03/doc1.xml…